Search

Giordano M Caponigro

from Foxboro, MA
Age ~58
Get Report
Also known as:
Giordano M Caponig, Gi Caponigro, Gordi M Hable, Michael Caponigro Giordano, Michael Caponigro Giordono, Giordani M Hable, Caponigro Giordano, Caponigro Glordano, Giordano R, Gi R
Phone and address:
6 Foxhill Rd, Foxborough, MA 02035
(508) 543-0574
Connected to:
Christine Caponigri, 56Elizabeth M Caponigro, 36Janine Caponigro, 44William K Capooth, 54Angela F Caporale, 76Elaine M Caporale, 59Gary J Caporale, 69Lori A Caporale, 49Louis A Caporale, 57Nina M Caporale, 53

Giordano Caponigro Phones & Addresses

  • 6 Foxhill Rd, Foxboro, MA 02035 (508) 543-0574
  • 677 7Th Ave, Salt Lake City, UT 84103 (801) 595-0607
  • 63 Hyde St, Newton Highlands, MA 02461 (617) 244-4574
  • Tucson, AZ
  • Newton Hlds, MA

Publications

Us Patents

Methods For Identifying, Characterizing, And Evolving Cell-Type Specific Cis Regulatory Elements

View page
US Patent:
6623922, Sep 23, 2003
Filed:
Feb 14, 1997
Appl. No.:
08/800664
Inventors:
Carl Alexander Kamb - Salt Lake City UT
Giordano M. Caponigro - Salt Lake City UT
Assignee:
Deltagen Proteomics - Wilmington DE
International Classification:
C12Q 168
US Classification:
435 6, 435 5, 435 691, 4353201, 435DIG 3, 435DIG 17, 435DIG 23, 435DIG 37, 536 231
Abstract:
The invention provides methods for efficient and rapid identification of cis-acting nucleic acid sequences that act in a cell-type specific manner to stimulate or repress the expression of linked genes or other neighboring sequences. The invention also provides methods for evolving novel regulatory sequences by in vitro manipulation of naturally occurring or synthetic cis acting nucleic acid sequences followed by screening and counterscreening steps. Furthermore, the invention provides methods for determining the mechanism by which cell-type specific cis regulatory sequences confer cell-type specific expression. Also provided are diagnostic methods based on the use of cell-type specific cis regulatory sequences.

Methods For Validating Polypeptide Targets That Correlate To Cellular Phenotypes

View page
US Patent:
20020045188, Apr 18, 2002
Filed:
May 25, 2001
Appl. No.:
09/865644
Inventors:
Carl Kamb - Salt Lake City UT, US
Giordano Caponigro - Salt Lake City UT, US
David Teng - Salt Lake City UT, US
Tanya Sandrock - Salt Lake City UT, US
Mark Stump - Salt Lake City UT, US
International Classification:
G01N033/53
G01N033/567
C12N015/63
US Classification:
435/007100, 435/007210, 435/455000
Abstract:
Generally applicable methods for identifying physiologically relevant endogenous target molecules, are provided. The methods use both protein interaction assay steps and phenotypic assay steps. In some embodiments, protein interactions are detected utilizing yeast two hybrid techniques.

Method For Treating Haematological Cancers

View page
US Patent:
20120258940, Oct 11, 2012
Filed:
Dec 17, 2010
Appl. No.:
13/516093
Inventors:
Giordano Caponigro - Foxborough MA, US
Diana Graus Porta - Basel, CH
Yao Yao - Shanghai, CN
Vito Guagnano - Basel, CH
International Classification:
A61K 31/573
A61P 35/00
US Classification:
514171
Abstract:
The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.

Methods For Identifying Agents That Cause A Lethal Phenotype, And Agents Thereof

View page
US Patent:
6582899, Jun 24, 2003
Filed:
Feb 15, 2000
Appl. No.:
09/504132
Inventors:
Carl Alexander Kamb - Salt Lake City UT
Giordano Michael Caponigro - Salt Lake City UT
Assignee:
Deltagen Proteomics, Inc. - Salt Lake City UT
International Classification:
C12Q 168
US Classification:
435 4, 435 6, 435 405
Abstract:
The present invention is directed to methods for performing negative selection assays leading to the identification of cytostatic or cytotoxic agents that cause a lethal phenotype. The invention is useful also for evaluation of conditional cytotoxicity and cell-specific cytotoxicity.

Mdm2 Inhibitors And Combinations Thereof

View page
US Patent:
20190060309, Feb 28, 2019
Filed:
Aug 24, 2016
Appl. No.:
15/756094
Inventors:
- Basel, CH
Giordano Caponigro - Foxborough MA, US
Joseph Lehar - Lexington MA, US
International Classification:
A61K 31/506
A61P 35/00
A61K 31/496
A61K 31/4184
A61K 31/4412
A61K 31/519
A61K 31/5377
A61K 31/4439
A61K 31/635
A61K 31/517
A61K 31/337
Abstract:
The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

Pharmaceutical Combination Comprising (A) The Alpha-Isoform Specific Pi3K Inhibitor Alpelisib (Byl719) And (B) An Akt Inhibitor, Preferably Mk-2206, Afuresertib Or Uprosertib, And The Use Thereof In The Treatment/Prevention Of Cancer

View page
US Patent:
20180256557, Sep 13, 2018
Filed:
Aug 24, 2016
Appl. No.:
15/754649
Inventors:
Giordano Caponigro - Foxborough MA, US
Joseph Lehar - Lexington MA, US
Samit Hirawat - Chatham NJ, US
International Classification:
A61K 31/4439
A61P 35/00
Abstract:
The present disclosure pertains to a pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor and (b) an AKT inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of such combination.

Combination Of Ribociclib And Dabrafenib For Treating Or Preventing Cancer

View page
US Patent:
20180250302, Sep 6, 2018
Filed:
Aug 25, 2016
Appl. No.:
15/755270
Inventors:
Giordano CAPONIGRO - Cambridge MA, US
Joseph LEHAR - Cambridge MA, US
International Classification:
A61K 31/519
A61P 35/02
Abstract:
The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an alpha-isoform specific phosphatidylinositol 3-kinase (PI3K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

Pharmaceutical Combination Comprising The Pi3K Inhibitor Alpelisib And The B-Raf Inhibitor Dabrafenib; The Use Of Such Combination In The Treatment Or Prevention Of Cancer

View page
US Patent:
20180243279, Aug 30, 2018
Filed:
Aug 24, 2016
Appl. No.:
15/755122
Inventors:
Giordano Caponigro - Foxborough MA, US
Joseph Lehar - Lexington MA, US
International Classification:
A61K 31/4439
A61P 35/02
Abstract:
The present disclosure relates to a pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Control profile
Giordano M Caponigro from Foxboro, MA, age ~58 Get Report